Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial
LANGHORNE, PA — Savara (Nasdaq: SVRA) reported new Phase 3 clinical trial data showing patients treated with its experimental inhaled therapy molgramostim achieved greater improvements in exercise capacity than those …
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial Read More